Mr. Gilliam has more than 25 years of experience in engineering, quality assurance and compliance for biopharmaceutical manufacturing facilities. His experience includes the development, implementation and management of Lean, Six Sigma programs and quality systems projects. Mr. Gilliam has led a variety of continuous improvement initiatives and has directed validation activities for capital projects with companies such as Talecris Biotherapeutics, Merck & Co. and Purdue Pharmaceuticals.
“We are pleased to welcome Elmer to IPS,” said Dave Goswami, PE, chairman and chief executive officer, IPS. “Elmer’s demonstrated leadership in validation project management, operational excellence, continuous improvement and quality assurances are tremendous assets for IPS, and will prove valuable to our clients as well.”